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AbstrACt
Objectives Schizophrenia is a chronic, debilitating 
psychiatric disease with highly variable treatment 
pathways and consequent economic impacts on resource 
utilisation. The aim of the study was to estimate the 
economic burden of schizophrenia in Italy for both the 
societal and Italian National Healthcare perspective.
Methods A probabilistic cost of illness model was applied. 
A systematic literature review was carried out to identify 
epidemiological and economic data. Direct costs were 
calculated in terms of drugs, hospitalisations, specialist 
services, residential and semiresidential facilities. Indirect 
costs were calculated on the basis of patients’ and 
caregivers’ loss of productivity. In addition, the impact of 
disability compensation was taken into account using a 
database from the Italian National Social Security Institute 
—Italy (INPS).
results Overall, 303 913 prevalent patients with 
schizophrenia were estimated. Of these, 212 739 (70%) 
were diagnosed and 175 382 (82%) were treated with 
antipsychotics. The total economic burden was estimated 
at €2.7 billion (95% CI €1771.93 to €3988.65), 50.5% 
due to indirect costs and 49.5% to direct costs. Drugs 
corresponded to 10% of direct costs and hospitalisations 
(including residential and semiresidential facilities) 
accounted for 81%.
Conclusions This study highlighted that indirect costs and 
hospitalisations (including residential and semiresidential 
facilities) play a major role within the expenses associated 
with schizophrenia in Italy, and this may be considered as 
a tool for public decision-makers.
IntrOduCtIOn 
Schizophrenia is considered among the most 
severe and debilitating mental disorders 
with enormous social and economic costs 
for the patients, caregivers and society as a 
whole.1 The epidemiological studies report 
a uniform prevalence rate among the most 
developed countries (0.3%–0.7%).2 3 The 
mortality rate is more than double4 than that 
of the general population, mainly due to 
suicides and cardiovascular diseases, with a 
higher risk of comorbidity (psychiatric and 
non-psychiatric).5 
The treatment and care of the patients with 
a diagnosis of schizophrenia accounts for 
between 1.5% and 3% of the total national 
health expense in the most developed coun-
tries,4 6 and 22%7 of the costs associated with 
mental disorders. In Europe, the economic 
impact is equal to 93.9 billion, of which 
69% is due to indirect costs only.1 In fact, it 
is estimated that the unemployment rate of 
patients with  schizophrenia is more than 
double than that of the general population,8 9 
and 51% of them receive a disability pension 
in Italy.8
As a consequence, indirect costs are a 
key aspect to estimate the overall impact 
of schizophrenia due to the precocity and 
chronic course of the illness, arising in most 
cases during adolescence.10 Furthermore, 
it is fundamental to efficiently allocate the 
economic resources in the therapeutic area. 
Therefore, major aspects are also the admin-
istration of highly effective drugs and the 
continuity of treatment. It has been proved, 
in fact, that non-adherence to drug treat-
ments is related to the flare of psychotic symp-
toms. This might result in the readmission to 
psychiatric wards or residential facilities and, 
consequently, higher costs for the National 
Health Service (NHS).7 For these reasons, 
non-adherence to treatment is the most 
common cause of rehospitalisation (about 
40% of new hospital admissions) and the risk 
of relapses, often characterised by episodes of 
greater severity.7 11 12
strengths and limitations of this study
 ► A bottom-up approach was used for estimating 
direct costs
 ► Human capital approach was used to calculate 
indirect costs
 ► The study may suffer from the standardisation of the 
retrieved data required to break down the population 
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This study was aimed at measuring the economic 
impact of schizophrenia in Italy, estimating the direct 
and indirect costs linked to the treatment, care and 
management of the diagnosed patients. The purpose was 
to conduct a systematic analysis of the existing literature 
and to create a probabilistic model to assess the annual 
economic burden for the NHS and for the society as a 
whole. The aim of this work was to present an overview 
of the resources used for the treatment and management 
of patients with  schizophrenia in Italy. The estimation of 
the annual economic burden may be considered as an 
insight in order to improve both the efficacy and effec-
tiveness of the patient care.
MethOds
A prevalence-based probabilistic model was used to 
calculate the aggregate measure of the economic impact 
associated with schizophrenia. Similar models have been 
previously applied in many studies and searches in the 
field of health economics evaluation13–22 to represent a 
1-year static estimation of the economic burden due to 
disease.
A bottom-up approach was used for estimating the total 
economic burden of schizophrenia from the societal 
perspective in Italy. This measure was obtained by taking 
into account the average costs per treatment multiplied 
by the prevalence of the population. Furthermore, the 
human capital approach was used to calculate indirect 
costs, considering the loss in productivity of both patients 
and their caregivers. Data included in the model were 
obtained from a systematic literature review conducted 
on the basis of the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses23 24 (online supplementary 
appendix, figure 1). The research was conducted in 
November 2015, and the last 10-year publications were 
examined. The analysis was performed through the online 
MEDLINE (Medical Literature Analysis and Retrieval 
System) bibliographic archive of MEDLARS, using the 
PubMed search system. In order to retrieve robust data 
specifically referred to the Italian context, the inquiry was 
integrated with the use of Google Scholar search engine 
and the database of the Italian specialised magazine 
reviews, along with the sources available to those involved 
in the project (clinicians and technicians). The key words 
used in the search were the following: cost of illness, cost, 
cost-benefit analysis, drug utilisation, prevalence, inci-
dence, schizophrenia and mental disorder (see online 
supplementary appendix, table 1). Study titles were 
evaluated, including those published in peer-reviewed 
scientific journals, in Italian or English, reporting epide-
miological or cost information preferably referring to the 
Italian context. Articles were selected and qualitatively 
analysed to identify information regarding any further 
aspects considering the treatment of schizophrenia that 
could be of interest for the purpose of current analysis 
(therapeutic pathways, health services and care provided 
at local level, etc). In order to reduce the possibility of 
report rejection, two investigators performed a blind 
reading of the materials, and any disagreement and risk 
of bias were solved through a discussion between the two 
review authors.23 24 In the following paragraphs, we will 
first present the structure of the model and report the 
deterministic estimations for both the epidemiological 
and cost parameters. In conclusion, we will illustrate the 
statistical analysis that we performed in order to take into 
account the variability of the data used in the probabi-
listic model.
Model structure
A breakdown of the schizophrenic population was 
defined and then used to build the model (figure 1). This 
was based on the epidemiological and cost data identified 
through the systematic review.
As a first aspect, the literature showed that more 
than 74% of patients interrupted the treatment before 
Figure 1 Breakdown of CoI model. FGA, first-generation antipsychotics; SGA, second-generation antipsychotics. 
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18 months.25 As previously indicated, in fact, only a 
percentage of diagnosed patients were actually identi-
fied and treated (82.4%).26 On the same line, the treated 
patients (TF) were defined as ‘patients  to whom a phar-
macological treatment is prescribed and the drug is actu-
ally administered’. Vice versa, not treated patients (NTF) 
were defined as ‘patients not receiving a prescription or 
not purchasing the prescribed drug’.
Second, data were broken down in relation to the cate-
gories of drugs that were currently administered: antipsy-
chotic therapy (N05A) and other CNS (central nervous 
system) drugs therapy. The administration practice of 
antipsychotic was distinguished into monotherapy and 
polytherapy. According to this study, patients under mono-
therapy were ‘subjects with a diagnosis of schizophrenia 
being treated with an antipsychotic without any additional 
concomitant CNS drugs within a year ’. Patients under 
polytherapy corresponded to the ‘patients with only one 
antipsychotic treatment plus additional CNS drugs’.26 
Therefore, in line with the National Ministerial Guide-
lines,27 only the therapeutic switch between first-genera-
tion and second-generation antipsychotics (FGA/SGA) 
was considered and not the contemporary intake (off 
label) of more antipsychotics for the same psychiatric 
disorder.
The stratification of the population, used to inform 
the probabilistic model, is showed in figure 1. This was 
obtained considering the opinions of the experts involved 
in the project and the analysis of previous contributions in 
this field according to the results of the literature review.
epidemiological parameters
Based on the systematic literature review, we considered 
the resident population in Italy on 1 January 2014, as esti-
mated by the Italian National Statistics Institute.28 To this 
figure, a prevalence of schizophrenia in Italy estimated as 
0.5% on the overall population was applied. This value 
was obtained considering the linear mean between the 
literature results and the expert opinion (0.3%–0.7%)2 3 
(online supplementary appendix, table 2).
The model assumed that 70% of the prevalent patients 
were actually diagnosed. This was obtained by making an 
average of the estimates reported by the Lazio Region in 
relation to the Mental Illness Centres (Centro di Salute 
Mentale—CSM) in 201229 and the opinions of clinicians 
involved in the current analysis regarding the real prac-
tice of their centres. Furthermore, from a study that 
assessed costs due to the treatment of schizophrenia from 
the perspective of Lombardia Region,26 it was consid-
ered that 82.4% of the diagnosed subjects were actually 
in treatment (TF) (range 74.9%–90.0%26 and expert 
opinion), while 17.6% (range 25.1%–10.0%26 and expert 
opinion) were not treated with antipsychotics or other 
drugs (NTF). According to these assumptions, patients 
being treated with monotherapy were estimated at 40% 
of the total number of treated patients with antipsychotics 
(range 20%–60%30), while those under polytherapy 
accounted for 60% (range 80%–40%30). Patients being 
treated with antipsychotics were further broken down 
according to the type of drug. It was assumed that 30.3% 
of total patients (range 20.8%–39.7%26 31) were treated 
with FGA26 31, 50.7% (range 37.6%–63.8%26 31) were 
treated with SGA and 19.1% (range 15.4%–22.7%26 31) 
(online supplementary appendix, table 2) with a combi-
nation of FGA and SGA.
Cost parameters
Direct costs were calculated based on the following 
parameters: drugs, hospitalisations, residential and semiresi-
dential facilities, and health specialist services such as psycho-
therapy and diagnostic examinations. In line with the 
Italian Ministry of Health,32 we distinguished between 
hospitalisations and residential facilities. The former are 
related to the management of acute events which require 
a variety of diagnostic and therapeutic options provided 
by hospitals. The latter provide assistance to the patients 
with stabilised clinical conditions who may require a 
long-term assistance, in relation to the chronicity of their 
illness. In Italy, this kind of services is coordinated at a 
local level by the Mental Illness Centres (CSM). Thus, in 
relation to the length of stay we were able to distinguish 
between residential facilities (Strutture residenziali) where 
patients can be assisted for more than 24 h and semiresi-
dential facilities (Centri Diurni) for day care.33
Cost parameters used to inform the probabilistic model 
were calculated by the type of treatment (monotherapy, 
polytherapy). In the online supplementary appendix 
tables 3–5, data used to calculate cost parameters are 
reported. Additionally, parameters are illustrated in terms 
of drug categories (FGA, SGA, FGA/SGA), and the data 
from the sources selected through our systematic litera-
ture review are reported.
From a methodological point of view, literature data 
were mainly used to estimate SGA treatments, as more 
sources were available. To estimate ‘Other drugs’ and 
‘Not treated (NTF)’ categories, only one literature source 
was taken into account.26 With reference to indirect costs, 
the loss of productivity of the patients and caregivers and 
the cost related to disability compensations were estimated. 
The loss of productivity was calculated in terms of missed 
access to the job market or unemployment rate caused 
by the disease. This was calculated by taking into account 
the differential between the percentage of unemployed 
people recorded in Italy in 201434 and that reported in 
literature and related to the subjects affected by schizo-
phrenia.8 9 In this regard, the cost due to the higher 
unemployment rate was obtained by multiplying the 
prevalence of unemployed patients with schizophrenia 
by the average income of the Italian population.35 The 
term ‘caregiver’ is referred to those subjects, such as 
family members, who provide care to the patient. Costs 
may be due, for example, to, ‘transportation to access 
treatment facilities and social care services’.26 To esti-
mate the burden related to this category, we considered 
the number of workdays that these subjects10 spend in 
supporting the patients with schizophrenia . This value 
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was multiplied by the Italian mean of income in 201435 to 
calculate the (crude) amount of the resources lost/used 
by these subjects.
Finally, about 51% of the patients received a pension.8 
This percentage was multiplied by the average of the 
disability compensations paid by the National Social Secu-
rity Institute in Italy.36 More specifically, only the disability 
pensions—and not the attendance allowance or inca-
pacity pensions paid by the State or other forms of finan-
cial support—were included. This permitted to obtain a 
more prudent estimate in line with the prevalence value 
indicated by the literature.
statistical analyses
In order to consider the variability of the data used to 
inform the model, a probabilistic approach was used 
(probabilistic sensitivity analysis). The analysis consists of 
using the differences found in the examined sources indi-
cating a minimum and maximum value of the uncertainty 
distribution of each parameter.
The probabilistic distribution was prepared applying 
what is normally reported for the development of prob-
abilistic models in economic evaluations, distinguishing 
between costs (gamma distribution) and epidemiolog-
ical parameters (beta distribution).37 Furthermore, the 
distribution of each parameter was used to perform 5000 
Monte Carlo simulations to obtain interval estimates 
(95% CI) of the main epidemiological and economic 
data.
Finally, in order to verify the uncertainty of the model, a 
one-way sensitivity analysis was performed, adjusting each 
parameter to the highest and lowest possible values of the 
data obtained in the systematic review of the literature. 
As average distribution value, the data of a particularly 
reliable source of the literature or the mean between 
minimum or maximum values were indicated, thus 
assuming an equal distribution of the values at the two 
extremes. This kind of analysis allows us to identify the 
parameters that mostly influence final cost variations asso-
ciated with schizophrenia. The definition of ‘possible’ for 
the highest and lowest values deriving from the analysis 
of the literature might vary from model to model, but it 
is usually reasonable to vary the parameters according to 
the CIs of the data.
results
According to our model estimates, in Italy 212 739 of 
subjects were diagnosed with schizophrenia in 2014. Of 
these, 175 382 were in treatment (82.4%), most of them 
(86.5%) with antipsychotics mainly associated with other 
CNS drugs (polytherapy 60%). About 57 000 patients 
were unemployed (27%) and 110 000 received a pension 
from the National Social Security Institution—Italy 
(INPS) (52%). Families and subjects taking care of the 
patients (caregivers) lost on average 44.1 working days a 
year in activities linked to the disease. According to the 
probabilistic estimates, the total cost of schizophrenia in 
Italy is €2 770 495 280 (95% CI €1771.93 to €3988.65). 
50.5% of this amount is due to indirect costs, while the 
remaining 49.5% to direct costs linked to the disease.
Overall, almost €1.37 billion (average 
1 372 779 860; 95% CI €850.88 to €2017.49) were 
the direct costs caused by schizophrenia and incurred 
by the NHS (figure 2). Of these, 81% were related 
to the aggregate of expenses due to hospitalisation 
(€218 855 113; 95% CI €131.14 to €328.67), residential 
facilities (€672 640 775; 95% CI €397.37 to €1019.18) 
and semiresidential facilities (€217 746 132; 95% CI 
€134.96 to €320.02). The drugs accounted for 10% 
(figure 2) with a yearly average expense of €135 911 253 
(95% CI €82.05 to €203.14). Health specialist 
services corresponded to 9%, €127 626 587 (95% CI 
€78.38 to €188.69).
Specifically, figure 3 and table 1 report the direct 
costs broken down by type of therapy. The patients in 
polytherapy accounted for €446.85 billion (95% CI 
€259.31 to €684.61), 53% of total costs of patients in 
treatment. The estimate of patients in monotherapy 
(33% of treated patients) is 272.92 billion (95% CI 
€139.04 to €451.19). For ‘Other CNS drugs’ and not 
treated patients, the expenses highlighted by the model 
accounted for 115.78 billion (95% CI €75.78 to €164.13) 
and 537.21 billion (95% CI €291.94 to €856.05). Figure 3 
shows the breakdown of the expenses according to the 
therapy followed by patients with schizophrenia. In case 
of monotherapy and polytherapy, the main expense item 
was that of semiresidential facilities, accounting for 26% 
and 24% of the total respectively, followed by hospital-
isation (24% monotherapy, 23% polytherapy) and drugs 
Figure 2 Direct costs and probabilistic results (95% CI), Euro million.
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(16% monotherapy, 19% polytherapy). Furthermore, 
88% (473.1 billion; 95% CI €257.1 to €753.89) of the 
costs of those patients who were not treated corre-
sponded to the residential facilities that also accounted 
for 39% of the total direct costs. On the other hand, resi-
dential facilities corresponded to 56% of costs related to 
patients treated with other CNS drugs (64.9 billion; 95% 
CI €42.48 to €92).
With reference to the indirect costs, the model esti-
mated an overall expense of €1 397 715 421 (95% 
CI €869.7 to €2048.97). The main cost item was that 
related to the loss of productivity, accounting for about 
60% of total indirect costs. The costs referred to the 
caregiver’s loss of productivity were 11% of the total 
indirect costs, while pension costs were 29% of the 
burden (figure 4).
Figure 3 Direct costs per year, Italy. 
Table 1 Direct cost per year, Italy
Cost item (mean annual cost)
Monotherapy
(Euro million)
Polytherapy
(Euro million)
Other drugs
(Euro million)
Not treated
(Euro million)
Drugs (95% CI) €42.95 
(€20.69 to €73.21) 
€85.84 
(€50.16 to €130.96) 
€7.11 
(€4.66 to €10.08) €0.00
Hospitalisation (95% CI) €65.96 
(€29.19 to €117.49) 
€104.20 
(€57.17 to €165.13) 
€15.04 
(€9.85 to €21.33) 
€33.63 
(€18.28 to €53.6) 
Residential facilities (95% CI) €52.26 
(€21.97 to €95.46) 
€82.36 
(€42.92 to €134.46) 
€64.90 
(€42.48 to €92) 
€473.10 
(€257.1 to €753.89) 
Semiresidential facilities (95% CI) €70.61 
(€36.69 to €115.46) 
€106.07 
(€62.08 to €161.67) 
€20.94 
(€13.71 to €29.69) 
€20.1 
(€10.93 to €32.04) 
Health specialist services (95% CI) €41.11 
(€21.12 to €67.67) 
€68.36 
(€39.66 to €104.75) 
€7.78 
(€5.09 to €11.03) 
€10.36 
(€5.63 to €16.51) 
Total (95% CI) €272.92 
(€139.04 to €451.19) 
€446.85 
(€259.31 to €684.61) 
€115.78 
(€75.78 to €164.13) 
€536.2 
(€291.94 to €856.05) 
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Figure 4 reports the data of the expenses indirectly 
linked to the disease in diagnosed subjects. The main item 
was that of the patients’ loss of productivity €844 448 270 
(95% CI €484.69 to €1302.43). The estimates of the 
pension burden (National Social Security Institution—
Italy (INPS) disability compensations) amounted to 
€404 436 141 (95% CI €251.09 to €593.75). Finally, the 
third expense item (11% of total indirect costs) is linked 
to the ‘lost’ work days of the caregiver, corresponding to 
€148 831 009 (95% CI €85.21 to €229.9).
dIsCussIOn
The study’s aim was to quantify the yearly mean cost for the 
care and management of the patients with schizophrenia 
in Italy. Consequently, in addition to the epidemiological 
relevance on total population (0.5%), decision-makers 
shall also take into account the significant economic 
impact of this disease. The results of our work, indeed, 
confirmed those of international literature about costs. 
They indicate that in Italy the total cost for society was 
approximately €2.7 billion. The need to quantify the 
impact of schizophrenia in Italy was due to the variety 
of the possible therapeutic pathways and the different 
approaches and methods in using FGA/SGA.
First of all, the breakdown of the expense for the care 
and management of schizophrenia showed the relevance 
of the indirect costs associated with it (€6614 per capita 
yearly), about €1.4 billion totally estimated by the model. 
These costs shall be duly taken into account, especially for 
diseases, such as schizophrenia, which require constant 
daily care and support by the families and society as a 
whole. It should be also considered that, according to 
international studies, schizophrenia is one of the first 10 
causes of severe and chronic disability.6 10 38 With refer-
ence to this, two main forms of care for schizophrenic 
subjects were identified and considered as a measure 
of the burden caused by the disease. First, we consid-
ered the care provided by the patient’s family (€689 
per capita yearly, on average); second, we measured the 
support provided through the National Social Security 
Institution—Italy (INPS) that was about €1863 yearly on 
average. Finally, we also identified the effect of the disease 
directly related to patients, impeding and hindering the 
access to the job market (€4062).
A key issue raised by the study concerned the number 
of not treated patients (NTF) involving an economic 
burden of over €14 000 per capita a year, compared with 
a mean of €4000 for treated patients. In terms of direct 
costs, untreated patients accounted for 40% of the total 
expense, even if they only represent 17.6% of the total 
diagnosed patients. With respect to the total economic 
burden, not treated patients (NTF) caused an annual 
expense of about €493 million only for residential and 
semiresidential facilities (18% of total expense of schizo-
phrenia in Italy) and over €43.7 million for hospitalisa-
tion and health specialist services. To our knowledge, this 
is the first study conducted in Italy estimating the total 
impact of schizophrenia using data from a systematic liter-
ature review and expert opinion. Based on this, a proba-
bilistic model was built, obtaining a macro value of the 
economic impact of schizophrenia in Italy. For diseases 
such as schizophrenia, often presenting conflicting guide-
lines and behaviours in the clinical practice, the analysis 
of the real practice is fundamental to correctly identify 
significant characteristics considered in this context. This 
is what emerged from main studies referred to Italy that 
were taken into account in building the cost and epide-
miological parameters included in the model. However, 
being mostly observational parameters,10 26 30 focused on 
specific types of treatments and care pathways linked to 
local reality, they did not help in obtaining a global esti-
mate of the specific aspects of schizophrenia and its total 
impact in terms of the resources used. Therefore, current 
analysis was exclusively referred to schizophrenia as iden-
tified with codes ICD10 (International Classification of 
Diseases, 10th edition) and not to the wider category of 
mental disorders. In addition to this, indirect costs were 
specifically analysed considering those presented as a 
significant cost item in literature, but never analysed in 
depth, in terms of its components.
One limit of the study may be the standardisation of the 
retrieved data required to break down the population. As 
highlighted in previous studies and by the information 
provided by the experts, the population breakdown was 
focused on the main expense items to be associated with 
NHS in Italy. The review allowed systematising the avail-
able information, but this may not be representative of 
the real practice on a national level. To fill this gap, the 
Figure 4 Indirect costs and probabilistic results (95% CI), Euro million.
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model proposed a well-validated probabilistic estimate 
method,13–22 considering the variability in the literature 
as minimum and maximum range in which it was highly 
possible to obtain the real inference estimate.
A second limit may be identified in the impossibility 
to obtain epidemiological sources and cost data from 
registry and/or administrative national data. Unfortu-
nately, these data are very difficult to be retrieved in Italy, 
where the fragmentary information at a regional level 
and the heterogeneity of the data collected do not allow 
to obtain adequate and representative samples.
Finally, there is an ongoing debate on whether disability 
pension should be included in the estimation of indirect 
costs.39 The criticism is referred to the possibility that 
they represent a transfer payment and their inclusion 
may result in a double counting estimation of the real 
economic burden from the perspective of the taxpayer 
rather than society. However, the Ministry of Economy 
through the general taxation funds disability pensions 
in Italy while the Social Security Institution—INPS is in 
charge of their disbursement.
COnClusIOn
In conclusion, this work represents a first attempt to fill 
the information gap on the yearly total expense and the 
cost breakdown of NHS and society to cure, treat and 
manage the patients affected with schizophrenia in Italy. 
These estimates may represent a useful tool for national 
and regional decision-makers to implement treatment 
policies and manage the patients in line with the specific 
context.
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